Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
If you are wondering whether Protagonist Therapeutics at around US$103.78 is still reasonably priced or already running ahead of itself, the valuation story is where your attention should be. The stock shows returns of 4.9% over 7 days, 13.5% over 30 days, 19.0% year to date, 133.5% over 1 year and roughly 5x over 3 years. These figures raise fair questions about how much of the story is already reflected in the price. Recent headlines around Protagonist Therapeutics have focused on its position in the biotech space and investor interest in its pipeline progress. This helps explain why the share price has been so active and provides important context when you are trying to decide whether to treat the recent run as justified enthusiasm or a source of extra risk. The company currently has a valuation score of . The next sections will compare what different valuation methods suggest about the stock while hinting at a more complete way to think about value that will be covered at t
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics Reports Granting of Inducement Awards [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) was given a new $121.00 price target by Truist Financial Corporation.MarketBeat
- Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Do Protagonist Therapeutics' (PTGX) Derisked Drugs Have Blockbuster Potential? [Yahoo! Finance]Yahoo! Finance
- J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]Yahoo! Finance
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 3/27/26 - Form 4
- 3/27/26 - Form 4
- 3/27/26 - Form 4
- PTGX's page on the SEC website